Derek Archila


Oppenheimer Makes Drastic Price Target Cut for Zynerba Pharmaceuticals Inc Following Epilepsy Drug Setback

Upon releasing negative data for lead drug candidate transdermal CBD (ZYN002) on Monday, Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) investors ran for the hills, sending …

Why Endo International plc (ENDP) Shares Could Remain Range-Bound

In a research report released Monday, Oppenheimer analyst Derek Archila reiterated a Perform rating on shares of Endo International plc (NASDAQ:ENDP), while estimating fair …

What To Expect Ahead of Synergy Pharmaceuticals Inc (SGYP) 2Q Earnings; Oppenheimer’s Take

Oppenheimer analyst Derek Archila sees some short-term capital rocky waters for Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and awaits more details post-Trulance launch, but continues to …

Trevena Inc (TRVN): Olinvo Remains Commercially Viable

Trevena Inc (NASDAQ:TRVN) shares collapsed today, falling nearly 40%, after the pharmaceutical company reported that both Phase 3 oliceridine (Olinvo) trials in post-surgical pain met …

Keep the Faith on Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Despite Short-Term Volatility: Oppenheimer

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares are falling nearly 7% following CEO Erez Vigodman’s exit, leaving current chairman Dr. Yitzhak Peterburg to …

Oppenheimer Chimes In On Synergy Pharmaceuticals Inc (SGYP) As Trulance Launch Expected In The Coming Weeks

Yesterday after the close, the FDA granted final approval to Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) Trulance (plecanatide), for the treatment of chronic constipation. However, Synergy …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts